 |
市場調查報告書
商品編碼
1907925
夜尿症市場：依藥物類別、給藥途徑、劑型、作用機轉、處方藥類型、年齡層、性別、通路、最終用戶及地區分類Nocturia Market, By Drug Class, By Route of Administration, By Dosage Form, By Mechanism of Action, By Prescription Type, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
價格
簡介目錄
夜尿症市場預計在 2025 年達到 44.1 億美元，預計到 2032 年將達到 76.1 億美元，2025 年至 2032 年的複合年成長率為 8.1%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2024 | 市場規模（2025 年） | 44.1億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期（2025-2032 年）複合年成長率 | 8.10% | 預計金額（2032 年） | 76.1億美元 |
全球夜尿症市場在更廣泛的泌尿系統和睡眠障礙藥物市場中佔據重要地位，它針對的是一種常見的疾病，其特徵是夜間需要醒來排尿。夜尿症影響著全球數百萬人，其盛行率隨著年齡的成長而顯著增加，並影響著各個年齡層的男性和女性。
這種疾病不僅會擾亂睡眠模式，還會對生活品質產生顯著影響，導致老年人白天疲勞、工作效率下降，並增加跌倒風險。市面上的治療方法多種多樣，包括藥物療法（如去氨加壓素、抗膽鹼能藥物和α阻斷劑）以及非藥物療法（如行為矯正和醫療設備） 。醫療專業人員越來越認知到，夜尿症是一種需要針對性治療性介入的獨立疾病，而不僅僅是潛在疾病的症狀。病患和醫療專業人員對現有治療方案的認知不斷提高，加上全球人口老化以及糖尿病、心臟衰竭和良性前列腺增生等相關合併症盛行率的上升，這些因素都在持續推動市場擴張和治療方案的創新。
市場動態
全球夜尿症市場主要受多種強勁因素驅動，這些因素共同創造了市場強勁成長和擴張的機會。其中最重要的促進因素是全球人口的快速老化。夜尿症的盛行率老齡化顯著增加，65歲以上族群的盛行率高達80%，擴大了需要治療性介入的患者族群。醫療專業人員和患者對夜尿症的認知不斷提高，他們逐漸意識到夜尿症是一種可治療的疾病，而非老齡化的必然組成部分，這促使診斷率提高，患者就醫意願增強。此外，糖尿病、心血管疾病和良性前列腺增生等潛在疾病的盛行率不斷上升，這些疾病都會導致夜間尿症的發生，進一步擴大了潛在患者族群。
然而，市場也面臨許多阻礙因素。患者認知不足導致診斷和治療延誤，許多患者將其視為老齡化的正常現象，並未尋求醫療干預。新藥認證的監管挑戰，特別是考慮到夜尿症病因複雜且需要全面的安全性評估，可能會延緩創新治療方法的上市。高昂的治療費用和某些治療方法的醫療覆蓋範圍有限，也可能阻礙患者獲得最佳治療。儘管有這些挑戰，市場也蘊藏著巨大的機遇，例如診斷工具的技術進步，使得患者分型更加精準，治療方案更加個人化。新型治療標靶和聯合治療的開發具有巨大的成長潛力，新興市場不斷完善的醫療基礎設施將為全球擴張的市場參與企業帶來新的收入來源。
本報告的主要特點
- 本報告對全球夜尿症市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和復合年成長率。
- 它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
- 全球夜尿症市場的主要企業將根據以下參數進行分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作關係、市場擴張和行銷策略做出明智的決策。
- 《全球夜尿症市場》報告面向該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球夜尿症市場的各種策略矩陣來更輕鬆地做出決策。
目錄
第1章 分析目標和先決條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 監管情景
- 產品發布/核准
- PEST分析
- 波特五力分析
- 企業合併情景
- 產業趨勢
4. 全球夜尿症市場按藥物類別分類（2020-2032 年）
- 抗利尿劑（例如，加壓素類似物，如去氨加壓素）
- α1腎上腺素受體拮抗劑（例如，Tamsulosin嗪、西洛多辛、特拉唑嗪）
- 促效劑（例如奧昔布寧、托特羅定、索利那新、達非那新、曲司氯銨）
- BETA3腎上腺素促效劑（例如，Mirabegron、維貝隆）
- 袢利尿劑給藥時間（例如，下午晚些時候服用Furosemide）
- 合併藥物治療（例如，Mirabegron+索利那新，α阻斷劑+抗膽鹼能藥物）
5. 全球夜尿症市場依給藥途徑分類（2020-2032 年）
- 口服
- 鼻腔
- 舌下給藥/口溶錠
- 腸外及其他全身給藥途徑
6. 全球夜尿症市場按劑型分類（2020-2032 年）
- 速釋片劑和膠囊
- 緩釋性/緩釋口服劑型
- 口溶錠和薄膜
- 滴鼻劑/鼻腔液
- 注射
7. 全球夜尿症市場依作用機轉分類（2020-2032 年）
- 血管加壓素受體促效劑
- 平滑肌鬆弛劑
- 毒蕈鹼受體阻斷劑
- BETA3受體促效劑
- 靶向前列腺鬆弛劑
- 體液調節調變器
8. 全球夜尿症市場依處方藥類型分類（2020-2032 年）
- 處方箋藥（Rx）
- 非處方藥
9. 全球夜尿症市場按年齡層別分類（2020-2032 年）
- 成人
- 老年人
第10章 全球夜尿症市場按性別分類（2020-2032 年）
- 男性
- 女士
第11章 全球夜尿症市場依通路分類（2020-2032 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第12章 全球夜尿症市場（按最終用戶分類）（2020-2032 年）
- 醫院
- 泌尿系統診所
- 長期照護機構及療養院
- 居家醫療/自我照顧環境
第13章 全球夜尿症市場區域分析（2020-2032 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第14章 競爭格局
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck &Co., Inc.
- Sanofi SA
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan（an AbbVie company）
第15章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map (COM)
第16章 參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI9058
Nocturia Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.10% | 2032 Value Projection: | USD 7.61 Bn |
The global nocturia market represents a critical segment within the broader urological and sleep disorder therapeutics landscape, addressing a prevalent medical condition characterized by the need to wake up during the night to urinate. Nocturia affects millions of individuals worldwide, with prevalence rates increasing significantly with age, impacting both men and women across various demographic groups.
This condition not only disrupts sleep patterns but also substantially affects quality of life, leading to daytime fatigue, reduced productivity, and increased risk of falls among elderly populations. The market encompasses various treatment modalities including pharmacological interventions such as desmopressin, anticholinergics, and alpha-blockers, alongside non-pharmacological approaches including behavioral modifications and medical devices. Healthcare providers increasingly recognize nocturia as a distinct medical condition requiring targeted therapeutic intervention rather than merely a symptom of underlying disorders. The growing awareness among patients and healthcare professionals about available treatment options, coupled with an aging global population and rising prevalence of associated comorbidities such as diabetes, heart failure, and benign prostatic hyperplasia, continues to drive market expansion and innovation in therapeutic solutions.
Market Dynamics
The global nocturia market is primarily driven by several compelling factors that collectively contribute to robust market growth and expansion opportunities. The most significant driver is the rapidly aging global population, as nocturia prevalence increases substantially with age, affecting up to 80% of individuals over 65 years, creating an expanding patient base requiring therapeutic intervention. Rising awareness among healthcare providers and patients about nocturia as a treatable medical condition rather than an inevitable aspect of aging has led to increased diagnosis rates and treatment seeking behavior. Additionally, the growing prevalence of underlying conditions such as diabetes mellitus, cardiovascular diseases, and benign prostatic hyperplasia, which contribute to nocturia development, further expands the potential patient population.
However, the market faces notable restraints including limited awareness among patients leading to underdiagnosis and undertreatment, with many individuals accepting the condition as a normal part of aging without seeking medical intervention. Regulatory challenges for new drug approvals, particularly given the complex etiology of nocturia and the need for comprehensive safety profiles, can delay market entry of innovative treatments. High treatment costs and limited insurance coverage for certain therapeutic options may restrict patient access to optimal care. Despite these challenges, significant opportunities exist through technological advancement in diagnostic tools enabling better patient stratification and personalized treatment approaches. The development of novel therapeutic targets and combination therapies presents substantial growth potential, while expanding healthcare infrastructure in emerging markets offers new revenue streams for market participants seeking global expansion.
Key Features of the Study
- This report provides in-depth analysis of the global nocturia market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nocturia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Ferring Pharmaceuticals, Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Avadel Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Urigen Pharmaceuticals Inc., Vantia Therapeutics Ltd., Viatris Inc., Allergan (an AbbVie company).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nocturia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nocturia market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intranasal
- Sublingual/orodispersible
- Parenteral and other systemic routes
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate-release tablets or capsules
- Modified/extended-release oral formulations
- Orodispersible tablets or film
- Nasal sprays or drops
- Injectable formulations
- Mechanism Of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Vasopressin Receptor Agonists
- Smooth Muscle Relaxants
- Muscarinic Receptor Blockers
- Beta-3 Receptor Stimulants
- Prostate-Targeted Relaxants
- Fluid-Regulation Modulators
- Prescription Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription-Only Medicines (Rx)
- Over-the-Counter Options (OTC)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty urology clinics
- Long-term care and nursing facilities
- Home-care and self-administration settings
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan (an AbbVie company)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Nocturia Market, By Drug Class
- Global Nocturia Market, By Route of Administration
- Global Nocturia Market, By Dosage Form
- Global Nocturia Market, By Mechanism of Action
- Global Nocturia Market, By Prescription Type
- Global Nocturia Market, By Age Group
- Global Nocturia Market, By Gender
- Global Nocturia Market, By Distribution Channel
- Global Nocturia Market, By End User
- Global Nocturia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Nocturia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Nocturia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sublingual/orodispersible
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral and other systemic routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Nocturia Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immediate-release tablets or capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Modified/extended-release oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Orodispersible tablets or film
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal sprays or drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Nocturia Market, By Mechanism of Action, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Vasopressin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Smooth Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscarinic Receptor Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Receptor Stimulants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate-Targeted Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluid-Regulation Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Nocturia Market, By Prescription Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription-Only Medicines (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter Options (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Nocturia Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Nocturia Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Nocturia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Nocturia Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care and nursing facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home-care and self-administration settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Nocturia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avadel Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Urigen Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vantia Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan (an AbbVie company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
